This week Verséa Ophthalmics team is presenting at the American Academy of Optometry AAOpt 2022 Meeting in San Diego (CA).
Visit our booth # 405, where we will be demonstrating our new Tear-Based Point of Care (T-POC) Quantitative Testing Platform that consists of a portable, multifunctional reader and two tear-based quantitative biomarker test kits:
– IgE Allergy Test Kit,
– Lactoferrin Dry Eye Test Kit.
In addition to the T-POC Quantitative Testing Platform, the team will be presenting new therapeutic solutions: a single and 3-layered decellularized, dehydrated human amniotic membranes (DDhAM) for ocular use, designed for comfort and improved handleability, available in multiple shapes and sizes.
Do not miss the opportunity to learn how our novel solutions can inform, guide, and enhance clinical management and treatment decisions that ultimately lead to better patient care!
About Verséa™ Ophthalmics
Verséa™ Ophthalmics, LLC, a business division of Verséa Holdings, Inc. (“Verséa”), is one of the fastest growing U.S. healthcare companies on a mission to revolutionize eye care. It is specialized in the sale and distribution of innovative solutions for the diagnosis, treatment, and management of ocular surface diseases. To learn more, visit Verséa™ Ophthalmics webpage
The new diagnostic platform is a result of an exclusive global commercial partnership with AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech” or “AXIM”), an international healthcare solutions company targeting ocular surface diseases.